vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
Ceribell, Inc. is the larger business by last-quarter revenue ($24.8M vs $12.8M, roughly 1.9× NextPlat Corp). NextPlat Corp runs the higher net margin — -40.2% vs -54.6%, a 14.4% gap on every dollar of revenue. NextPlat Corp produced more free cash flow last quarter ($-339.0K vs $-11.0M).
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
CBLL vs NXPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $12.8M |
| Net Profit | $-13.5M | $-5.1M |
| Gross Margin | 87.3% | 14.3% |
| Operating Margin | -58.9% | -28.9% |
| Net Margin | -54.6% | -40.2% |
| Revenue YoY | — | -21.1% |
| Net Profit YoY | — | -70.6% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | $12.8M | ||
| Q3 25 | $22.6M | $13.8M | ||
| Q2 25 | $21.2M | $13.2M | ||
| Q1 25 | $20.5M | $14.5M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | $17.2M | $15.4M | ||
| Q2 24 | — | $17.0M | ||
| Q1 24 | — | $17.5M |
| Q4 25 | $-13.5M | $-5.1M | ||
| Q3 25 | $-13.5M | $-2.2M | ||
| Q2 25 | $-13.6M | $-1.8M | ||
| Q1 25 | $-12.8M | $-1.3M | ||
| Q4 24 | — | $-3.0M | ||
| Q3 24 | $-10.4M | $-4.2M | ||
| Q2 24 | — | $-5.3M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | 87.3% | 14.3% | ||
| Q3 25 | 88.3% | 19.9% | ||
| Q2 25 | 88.1% | 21.8% | ||
| Q1 25 | 87.9% | 23.8% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | 87.3% | 23.2% | ||
| Q2 24 | — | 34.5% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | -58.9% | -28.9% | ||
| Q3 25 | -64.8% | -14.5% | ||
| Q2 25 | -70.5% | -13.8% | ||
| Q1 25 | -69.3% | -10.2% | ||
| Q4 24 | — | -14.1% | ||
| Q3 24 | -57.8% | -52.1% | ||
| Q2 24 | — | -64.1% | ||
| Q1 24 | — | -10.5% |
| Q4 25 | -54.6% | -40.2% | ||
| Q3 25 | -59.6% | -15.9% | ||
| Q2 25 | -64.4% | -13.5% | ||
| Q1 25 | -62.4% | -9.2% | ||
| Q4 24 | — | -18.6% | ||
| Q3 24 | -60.6% | -27.4% | ||
| Q2 24 | — | -31.3% | ||
| Q1 24 | — | -8.5% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.37 | — | ||
| Q2 25 | $-0.38 | — | ||
| Q1 25 | $-0.36 | $-0.05 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.85 | $-0.22 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | $13.7M |
| Total DebtLower is stronger | — | $1.3M |
| Stockholders' EquityBook value | $155.3M | $17.3M |
| Total Assets | $195.8M | $27.5M |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | $13.7M | ||
| Q3 25 | $168.5M | $13.9M | ||
| Q2 25 | $177.4M | $16.6M | ||
| Q1 25 | $182.7M | $17.7M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | $14.1M | $20.4M | ||
| Q2 24 | — | $24.9M | ||
| Q1 24 | — | $23.5M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $155.3M | $17.3M | ||
| Q3 25 | $164.1M | $21.4M | ||
| Q2 25 | $172.2M | $23.5M | ||
| Q1 25 | $180.9M | $25.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | $-136.0M | $22.5M | ||
| Q2 24 | — | $26.5M | ||
| Q1 24 | — | $31.2M |
| Q4 25 | $195.8M | $27.5M | ||
| Q3 25 | $199.5M | $30.0M | ||
| Q2 25 | $207.7M | $31.0M | ||
| Q1 25 | $213.5M | $35.2M | ||
| Q4 24 | — | $37.1M | ||
| Q3 24 | $47.1M | $41.1M | ||
| Q2 24 | — | $51.5M | ||
| Q1 24 | — | $65.1M |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $-302.0K |
| Free Cash FlowOCF − Capex | $-11.0M | $-339.0K |
| FCF MarginFCF / Revenue | -44.2% | -2.6% |
| Capex IntensityCapex / Revenue | 0.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | $-302.0K | ||
| Q3 25 | $-11.1M | $-2.7M | ||
| Q2 25 | $-7.5M | $-1.0M | ||
| Q1 25 | $-11.4M | $-2.1M | ||
| Q4 24 | — | $-476.0K | ||
| Q3 24 | — | $-4.6M | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | — | $-2.7M |
| Q4 25 | $-11.0M | $-339.0K | ||
| Q3 25 | $-11.5M | — | ||
| Q2 25 | $-7.6M | $-1.1M | ||
| Q1 25 | $-11.6M | $-2.1M | ||
| Q4 24 | — | $-508.0K | ||
| Q3 24 | — | $-4.7M | ||
| Q2 24 | — | $2.2M | ||
| Q1 24 | — | $-2.7M |
| Q4 25 | -44.2% | -2.6% | ||
| Q3 25 | -50.8% | — | ||
| Q2 25 | -35.9% | -8.0% | ||
| Q1 25 | -56.4% | -14.3% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | — | -30.6% | ||
| Q2 24 | — | 13.2% | ||
| Q1 24 | — | -15.7% |
| Q4 25 | 0.7% | 0.3% | ||
| Q3 25 | 1.6% | 0.0% | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | 0.7% | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
